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Background: Studies have demonstrated lower rates of breast cancer survival for Black versus White women.
Factors implicated include later stages at diagnosis, differences in tumor biology, and lower compliance rates to
adjuvant hormone therapy (AHT) among Black women with hormone sensitive breast cancer. We examined factors
associated with compliance to AHT among Black and White women with invasive breast cancer.
Methods: Women with estrogen receptor positive (ER+), non-metastatic breast cancer were identified by the
cancer registry at the University of Chicago Hospital and asked to complete a mail-in survey. Compliance was
defined by self-reported adherence to AHT ≥80% at the time of the survey plus medical record verification of
persistence (completion of 5 years of AHT). Logistic regression was used to determine factors associated with
compliance to AHT.
Results: 197 (135 White and 62 Black) women were included in the analysis. 97.4% of patients reported adherence
to therapy. 87.4% were found to be persistent to therapy. Overall compliance was 87.7% with no statistically
significant racial difference seen (87.9% in White and 87.0% in Black, P = 0.87). For both Black and White women,
compliance was strongly associated with both perceived importance of AHT (OR =2.1, 95% CI:1.21-3.68,P = 0.009)
and the value placed on their doctor’s opinion about the importance of AHT (OR = 4.80, 95% CI: 2.03-11.4,
P < 0.001).
Conclusions: In our cohort of Black and White women, perceived importance of AHT and the degree to which
they valued their doctor’s opinion correlated with overall compliance. This suggests that Black and White women
consider similar factors in their decision to take AHT.
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An estimated 75% of breast cancers express estrogen and/
or progesterone receptors. For women with these cancers,
treatment with five years of adjuvant hormone therapy
(AHT), either tamoxifen or an aromatase inhibitor, has
been shown to decrease the risk of both breast cancer re-
currence and mortality by about a third throughout the
first 15 years (Davies et al. 2011). Recent data has shown* Correspondence: shong@medicine.bsd.uchicago.edu
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ease for 10 years produces a further reduction in recur-
rence and can approximately halve breast cancer mortality
during the second decade after diagnosis (Davies et al.
2013; Gray et al. 2013). Despite these benefits, studies
have demonstrated adherence rates to range from 41% to
72% and non-persistence (discontinuation of therapy be-
fore completion of 5 years) to range from 31% to 73%.
Previous studies have identified multiple risk factors for
therapy noncompliance including extremes of age (Barron
et al. 2007), concomitant antidepressant use (Demissie
et al. 2001), lack of social support (Kahn et al. 2007),n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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et al. 2012). Ethnic and racial variations in medication
compliance have also been demonstrated. A number of
studies show lower rates of compliance and an increase in
mortality among ethnic minorities, particularly Black
women (Patridge 2003; Kim et al. 2008; Hershman et al.
2011; Hershman et al. 2009). Studies aimed at improving
compliance rates have largely focused on reducing the
negative side effects of therapy, however; a number of
women do not experience adverse effects and are still
noncompliant. Identifying modifiable factors contributing
to therapy noncompliance may have significant benefits
in improving breast cancer survival.
Models from health psychology have been applied to
studies of medication compliance (Kucukarslan 2012).
Social cognition models such as the health belief model
assumes that individuals develop beliefs that influence
the interpretation of information and guide behavior
(Horne & Weinman 1999). A number of studies have in-
vestigated the impact of perceived benefit of AHT on
compliance rates (Barron et al. 2007; Lash et al. 2006;
Grunfeld et al. 2005; Fink et al. 2004; Cluze et al. 2012;
Kirk & Hudis 2008; Pellegrini et al. 2010; Thewes et al.
2005; Kimmick et al. 2009; Shelton et al. 2013). Grunfeld
and colleagues found that adherers were more likely to
report a belief in tamoxifen benefit whereas non-
adherers were more likely to report no benefit (Grunfeld
et al. 2005). In a follow-up study conducted two years
after initiation of therapy, Fink and colleagues found that
patients’ perceived risk versus benefit of tamoxifen was
critical to sustaining adherence after the immediate
threat of a breast cancer diagnosis had passed (Fink
et al. 2004). Other studies demonstrate a correlation be-
tween perceived benefit and future compliance. In a
follow-up study of elderly women conducted 5-years
after initiation of therapy, Lash and colleagues found
that the perceived benefit of therapy assessed at baseline
corresponded to future compliance (Lash et al. 2006).
Few studies have examined the association of race with
attitudes regarding adjuvant hormone therapy. Shelton
and colleagues found significant differences in provider
communication, patient involvement in decision making,
and medical trust by race of patients (Shelton et al. 2013).
However, to the best of our knowledge, no study has spe-
cifically assessed whether or not differences in perceived
benefit of AHT exists between Black and White women
and how this impacts overall compliance rates.
Our study sought to examine factors associated with
compliance to AHT in Black and White women with
ER + breast cancer at a tertiary urban medical center.
Participants and methods
This research was approved by the University of Chicago
institutional review board and patients provided writteninformed consent for survey participation and retro-
spective data analysis.
Study sample
Women who had ER + breast cancer were identified by
the cancer registry at the University of Chicago. Patients
were eligible for this study if they were English speaking,
under 80 years of age at initial cancer diagnosis, were no
more than 10 years out from their cancer diagnosis, and
had been offered hormone therapy [either tamoxifen
or an aromatase inhibitor (letrozole, anastrozole, or
exemestane)] as part of their post-surgery treatment.
Women with stage IV breast cancer, history of cancer
prior to their breast cancer diagnosis, or a known
BRCA1/2 germ-line mutation were excluded from the
study.
Survey
We designed and implemented a paper survey to assess
factors associated with self-reported adherence to AHT.
Patients were asked to self-report demographic variables
such as race, income, and education. In addition, pa-
tients were asked questions about pre-existing chronic
health conditions such as diabetes and hypertension, the
number of prescription medications taken, whether or
not they had insurance coverage for their medications,
their total out-of-pocket cost of medications per month,
and perceived risk for breast cancer recurrence. The
Survey Research Lab at the University of Chicago
conducted pretesting of the survey questions to assess
both validity and reliability. All eligible patients (N =
381) were contacted by telephone and then mailed the
15 page self- administered survey. Regardless of survey
completion, all participants were given a $10 dollar gift
card.
To assess adherence, women were asked how often
they missed their adjuvant hormone therapy on six cat-
egories: 1) never missed a dose; 2) missed no more than
1 dose per month; 3) missed no more than 2 doses per
month; 4) missed 1–2 doses per week; 5) missed ≥3
doses per week; and 6) never took the therapy. Regard-
less of whether or not they chose to start AHT, partici-
pants were asked how important they thought AHT was
in decreasing their risk for breast cancer recurrence (not
important, a little important, moderately important, or
very important). Participants were also asked how wor-
ried they were about their risk for breast cancer recur-
rence (very, somewhat, or not worried) and how this
compared to their fears at the time of their cancer diag-
nosis. Other questions included how worried they were
about the long-term side effects of taking AHT and con-
cerns about their overall medication costs and the po-
tential for AHT to interfere with their other medicines.
In addition, participants were asked how heavily they
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or not take adjuvant hormone therapy (almost entirely,
partly, or not at all).
Measurements
Prior studies using both self- report and pharmacy pre-
scription refill records have used an 80% cut-off to de-
fine adherence since <80% adherence has been
associated with increased mortality (Kahn et al. 2007;
Molfenter et al. 2012; Stavropoulou 2011). Thus we
defined adherence in our cohort by self report of tak-
ing ≥ 80% of prescribed pills on average per month and
patients were considered non-adherent if they missed
greater than or equal to 3 doses per week on average
(which corresponded to taking therapy less than 80% of
the time per month) or if they had not initiated therapy
at the time of the survey.
Persistence was defined as completion of 5 years of ther-
apy and was verified by chart review. Chart review docu-
mentation in clinic notes from the breast surgeon,
radiation oncologist, or medical oncologist were used to
assess completion of 5 years of AHT. At the time of chart
review, 25 women (12.6%) were in their fourth year of
therapy. These women were included as having completed
5 years of AHT. We felt this was appropriate since prior
studies have shown that women who have taken most
of their therapy are very likely to complete therapy
(Molfenter et al. 2012). We also conducted sensitivity ana-
lyses by including and then excluding these 25 women
and found no difference in either persistence rates or pre-
dictors of persistence. Patients with missing data were
excluded from the overall analysis.
Compliance was defined as a composite of being both
adherent and persistent. Of the women who were found
to be persistent, only one patient (0.7%) reported non-
adherence. Therefore, our definition of compliance relies
heavily on persistence.
Statistical analysis
All statistical analyses were conducted with Stata 12.1
(StataCorp, College Station, TX, USA). Demographic
characteristics and variables previously mentioned were
compared for adherence and compliance rates using a
Spearman’s rank correlation or Kruskal-Wallis test. Ori-
ginally, adherence to hormone therapy was measured as
a 6-scale ordinal outcome based on self-report. However,
the categories for non-adherence were very small, and
thus were combined into one category. We used logistic
regression models to evaluate how perceived importance
of therapy, concern about breast cancer recurrence, con-
cern about side effects of therapy, and how heavily they
valued their doctor’s opinion factored into their decision
to adhere and complete therapy. Self- reported race and
value placed on their doctor’s opinions were adjusted inthe multivariable model to remove confounding effects
(Model B) and is considered the full model. Concern
about side effects was tested as an additional confounder
(Model C) but was not included in the full model. To
test if the associations differed by race, we generated an
interaction term between race and the variable of inter-
est, and used the Likelihood-ratio test to determine if
the interaction was significant.Results
Patient demographics/characteristics
Of the original 381 women who were asked to partici-
pate in the study, 226 (59.3%) completed the survey.
Thirteen (6%) were excluded because they did not meet
inclusion criteria and 15 (7%) were excluded from the
analysis because they did not self-report race as either
White or Black. Therefore survey data for 197 (87%)
women (135 (68.5%) White and 62 (31.5%) Black) were
available. Adherence information was available for 192
of the 197 women (5 were excluded due to missing in-
formation). Medical records were available for persist-
ence information on 166 out of 197 women. However
only 162 women had complete information on both ad-
herence and persistence and thus we were able to assess
overall compliance on 162 women.
Patient demographics including age, income, education
level and co-morbid conditions are described in Table 1.Overall compliance/adherence
Self-report of medication adherence was high, with 187/
192 (97.4%) reporting adherence to therapy (98.5% in
White versus 94.9% in Black, p = 0.15). Only 5/192
(2.6%) reported either never starting AHT or missing
their doses an average of ≥3 times per week. 87.3%%
(145/166) were found to be persistent to therapy on
chart review (88.1% in White versus 85.4% in Black, p =
0.63). Overall compliance was 87.7% (142/162) with no
statistically significant racial difference seen (87.9% in
White and 87.0% in Black, p = 0.87).Predictors of compliance/adherence
Race and additional demographic characteristics
In univariate analysis shown in Table 2, compliance rates
were similar between White and Black women (87.9%
vs. 87.0%, P = 0.63). Compared to White women, Black
women, had lower education and income levels and
more comorbid conditions. Black women, however, had
better insurance coverage for prescription medications
compared to White women. None of these variables
were significantly associated with adherence or compli-
ance (Table 2).
Table 1 Characteristics of black and white women
N (%)
White Black Total
N = 135 N = 62 N = 197
Age (mean; range)♦ 58.0; 39-72 58.1; 42-73 58.1; 39-73
Education level+
< High school 8 (5.9%) 9 (14.5%) 17 (8.6%)
High school graduation 52 (38.5%) 33 (53.2%) 85 (43.2%)
Bachelor’s degree 31 (23.0%) 8 (12.9%) 39 (19.8%)
Graduate degree 44 (32.6%) 12 (19.4%) 56 (28.4%)
Income+
<60 K 40 (29.6%) 38 (61.3%) 78 (39.6%)
60 K + 89 (65.9%) 16 (25.8%) 105 (53.3%)
Unknown 6 (4.4%) 8 (12.9%) 14 (7.1%)
Comorbid Medical Conditions+^
None 52 (38.5%) 11 (17.7%) 63 (32.0%)
>1 comorbid condition 83 (61.5%) 51 (82.3%) 134 (68.0%)
Insurance coverage+
None 0 (0%) 3 (4.8%) 3 (1.5%)
Some 33 (24.4%) 8 (12.9%) 41 (20.8%)
Most 92 (68.2%) 40 (64.5%) 132 (67.0%)
All 8 (5.9%) 10 (16.3%) 18 (9.1%)
Unknown 2 (1.5%) 1 (1.6%) 3 (1.5%)
Out of pocket expenses♦
None 1 (0.7%) 2 (3.2%) 3 (1.5%)
<$50/month 43 (31.9%) 31 (50.0%) 74 (37.6%)
$50-100/month 43 (31.9%) 16 (25.8%) 59 (30.0%)
$100-150/month 25 (18.5%) 5 (8.1%) 30 (15.2%)
$150-200/month 5 (3.7%) 4 (6.5%) 9 (4.6%)
$ > $200/month 7 (5.2%) 1 (1.6%) 8 (4.1%)
Unknown 11 (8.2%) 3 (4.8%) 14 (7.1%)
+P-values < 0.05 by Chi-Square test.
♦P-values >0.05 by Chi-Square test?
^ Diabetes on medication, hypertension on medication, high cholesterol on
medication, kidney disease, and peripheral vascular disease.
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As shown in Table 3, women who perceived therapy to
be “very important” were significantly more compliant
than those who perceived therapy to be “not important”
(adjusted OR = 9.82, 95% CI:1.75-55.1). For this 4-scale
variable, per-unit increase was associated with an OR of
2.11 (95% CI: 1.21-3.68). When examining perception of
hormone therapy importance by race, no difference was
seen between Black and White women (P-interaction =
0.99). Black women were as likely as White women to
perceive AHT as important.
Compliance/adherence by value of Doctor’s opinion
Value placed on doctor’s opinion was another strong
predictor of compliance. As shown in the multivariableanalysis in Table 3, women who valued their doctor’s opin-
ion heavily were significantly more compliant than those
who did not (adjusted OR = 45.7, 95% CI: 3.54-590.2).
Per-unit increase of this 3-scale variable was associated
with an OR of 4.80 (95% CI: 2.01-11.4) for compliance.
Discussion
We found that for both Black and White women, per-
ceived importance of AHT in reducing their risk for
developing recurrent breast cancer and the degree to
which they valued their doctor’s opinion were the most
important factors contributing to their overall compli-
ance to therapy. Interestingly, education, income, con-
cerns surrounding medication side effects, and out of
pocket expenses did not appear to significantly impact
reported rates of either therapy adherence or overall
compliance in our cohort. Thus perception of the
importance of AHT and enhanced doctor-patient
communication may be important modifiable factors
that can improve compliance to AHT.
In our study, patients who significantly valued their
doctor’s opinions in general were more compliant to
therapy. The doctor-patient relationship (Stavropoulou
2011) and doctor-patient communication (Bultman &
Svarstad 2000) has been studied extensively in the adher-
ence literature. Studies examining barriers to statin com-
pliance have found communication patterns between
patients and their clinical providers influence statin-
adherence behaviors (McGinnis et al. 2007) and medical
outcomes (Molfenter et al. 2012; Kaplan et al. 1989).
Although a recent randomized prospective study exam-
ining the influence of educational materials on adher-
ence to aromatase inhibitors found no difference in
compliance and persistence between groups that re-
ceived the educational materials versus those that did
not, it is likely that educational materials alone may not
be sufficient and a multidisciplinary approach is required
(Yu et al. 2012). Further supporting this is a study by
Shelton and colleagues which examines doctor-patient
communication in patients receiving adjuvant therapy
(including chemotherapy) for breast cancer. They
found that enhanced provider contact increased com-
pliance rates (Shelton et al. 2013). Thus doctor-patient
communication beyond the distribution of educational
materials is one possible modifiable mechanism to im-
prove compliance.
One strength of our study is our ability to link chart
review with survey responses. We were able to correl-
ate patients’ perceived benefit of AHT and reported
adherence rates with eventual completion of AHT as
documented by medical records in a cohort study
design, which enhances causal inference.
A limitation of our study is the use of a self-reported
adherence by survey participants. We recognize that
Table 2 Compliance to adjuvant hormone therapy by patient characteristics
Total N Not compliant Compliant OR 95% CI
Age in years
39-50 18 1 (5.6%) 17 (94.4%) 1.0 (Ref)
51-60 81 12 (14.8%) 69(85.2%) 0.34 0.41-2.78
61-74 61 7 (11.5%) 54 (88.5%) 0.45 0.05-3.95
Race/Ethnicity
White 116 14 (12.1%) 102 (87.9%) 1.0 (Ref)
Black 46 6 (13.0%) 40 (87.0%) 0.92 0.33-2.55
Insurance coverage on prescriptions
None 2 0 (0%) 2 (100%) 1.0 (Ref)
Some 37 5 (13.5%) 32 (86.5%) 0.46 0.05-4.28
Most 105 14 (13.3%) 91 (86.7%) 1.45 0.06-3.81
All 15 1 (6.7%) 14 (93.3%) - -
Family income
<$60 K 61 5 (8.2%) 56 (91.8%) 1.0 (Ref)
$60 K+ 91 13 (14.3%) 78 (85.7%) 0.54 0.18-1.59
Education level
< High school 15 1 (6.7%) 14 (93.3%) 1.0 (Ref)
High School Graduate 65 7 (10.8%) 58 (89.2%) 0.59 0.07-5.21
Bachelor’s Degree 33 5(15.2%) 28(84.9%) 0.40 0.04-3.76
Graduate Degree 49 7 (14.3%) 42 (85.7%) 0.42 0.05-3.79
Comorbid Medical Conditions
None 54 6 (11.1%) 48 (88.9%) 1.0 (Ref)
≥1comorbid conditions 108 14 (13.0%) 94 (87.0%) 0.84 0.30-2.32
Out of pocket expenses
None 1 0 (0%) 1 (100%)
<$50/month 60 8 (13.3%) 52 (86.7%) 1.0 (Ref)
$50-100/month 47 6 (12.8%) 41 (87.2%) 1.05 0.34-3.27
$100-150/month 26 2 (7.7%) 24 (92.3%) 1.84 0.36-9.36
$150-200/month 8 2(25.0%) 6 (75.0%) 0.46 0.08-2.70
>$200/month 8 0 (0%) 8 (100%) - -
Perceived importance of therapy
Not important 9 4 (44.4%) 5 (55.6%) 1.0 (Ref)
A little important 7 3 (42.9%) 4 (57.1%) 1.07 0.14-7.82
Moderately important 38 5(13.2%) 33 (86.8%) 5.28 1.05-26.6
Very important 104 7 (6.7%) 97 (93.3%) 11.1 2.42-50.8
Concern about cancer recurrence
Not worried 51 6 (11.8%) 45 (88.2%) 1.0 (Ref)
Somewhat worried 86 13 (15.1%) 73 (84.9%) 0.75 0.27-2.11
Very worried 24 1 (4.2%) 23 (95.8%) 0.75 0.35-27.0
Concern about side effects
Not concerned 40 4 (10.0%) 36 (90.0%) 1.0 (Ref)
Small concerns 50 6 (12.0%) 44 (88.0%) 0.81 0.21-3.11
Moderate concerns 42 2 (4.8%) 40 (95.2%) 2.22 0.38-12.9
Big concerns 29 8 (27.6%) 21 (72.4%) 0.29 0.08-1.09
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Table 2 Compliance to adjuvant hormone therapy by patient characteristics (Continued)
Value placed on doctor’s opinion
Not at all 7 6 (85.7%) 1 (14.3%) 1.0 (Ref)
Partly 23 5 (21.7%) 18 (78.3%) 21.6 2.09-223.7
Almost entirely 131 9 (6.9%) 122 (93.1%) 81.3 8.81-750.8
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who do not (Font et al. 2012). Although our study re-
sults suggest that Black and White survey participants
who perceive AHT as important are also more likely to
be both adherent and compliant to therapy, it is un-
clear if this observation holds for nonparticipants.
Contrary to other studies examining compliance to
therapy, we found no significant difference in reported
adherence or overall compliance rates between Black
and White women. Several explanations are possible.
Although Black women in our study had lower
education levels, lower income levels, and more
chronic health conditions, Black women had better in-
surance coverage for medications compared to White
women. Thus Black women who participated in our
survey had greater access to medications than White
women. Another possible explanation is that our studyTable 3 Multivariable analysis of compliance by logistic regre
Model A
OR 95% CI P
Perceived importance of therapy
Not important 1.0 (Ref)
A little important 1.00 0.13-7.48
Moderately important 5.91 1.13-30.9 0.003














Big concernsmay have been underpowered. Although we had
enough power to detect a greater than 15% difference
in compliance rates it is possible that true compliance
rates differ by less than 15%.
Given the increase in the number of oral anti-cancer
medications, identifying modifiable barriers to the use
of oral therapy, especially in minority women, is
critical to improving survival. Prospective studies
examining factors associated with non-initiation, non-
adherence, and early discontinuation of adjuvant
hormone therapy are underway with special attention
to ethnic minorities (Neugut et al. 2012). Perceived
therapy importance and doctor-patient communica-
tion on medication compliance represent modifiable
variables which can improve overall cancer survival.
Further prospective studies are needed to validate
these findings.ssion
Model B: Full model Model C
OR 95% CI P OR 95% CI P
1.0 (Ref) 1.0 (Ref)
3.40 0.17-67.8 4.12 0.17-98.9 0.16
5.81 0.94-35.9 0.08 5.17 0.74-36.0
9.82 1.75-55.1 8.50 1.32-54.7
2.11 1.21-3.68 0.009 2.18 1.24-3.84 0.007
1.0 (Ref) 1.0 (Ref) 0.54
1.66 0.43-6.35 0.46 1.52 0.40-5.73
1.0 (Ref) 1.0 (Ref)
13.3 0.88-201.2 0.004 17.9 1.02-315.2 0.007
45.7 3.54-590.2 54.8 3.73-805.9
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